Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

Fintel reports that on July 23, 2025, Barclays downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 725.97% Upside As of July ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Fintel reports that on July 22, 2025, Leerink Partners downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Market Perform. Analyst Price Forecast Suggests 725.97% Upside As ...

Iova stock jumps 31% amid FDA setback for rival, short squeeze buzz, and rising momentum for Amtagvi melanoma therapy.

Vir Biotechnology has a strong cash position and is poised to generate definitive data in antivirals and oncology, making ...

Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the ...

Northern Trust Corp (NTRS) is expected to report $2.05 for 2Q. Otis Worldwide Corp (OTIS) is expected to report $0.93 for 2Q. PROG Holdings Inc (PRG) is expected to report $0.74 for 2Q. Pacific ...

Kennedy Jr. sued him in his capacity as HHS secretary for not establishing a task force to promote the development of safer ...

A new biotech called Dispatch Bio launched today with the goal of developing a new, universal approach to try to treat any cancer using immunotherapy.